# Atezolizumab

## Tecentriq inj 1200mg/20mL

| 藥物代碼           | ITEC                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                              |
|:-------------------|:------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| 適應症             | Locally advanced or metastatic urothelial carcinoma (UC) after prior chemotherapy, or for those considered cisplatin ineligible & whose tumours have a PD-L1 expression ?5%, or those not eligible for any platinum-containing chemotherapy regardless of tumor PD-L1 expression level. 1st-line treatment in combination w/ bevacizumab, paclitaxel & carboplatin for metastatic non-squamous non-small cell lung cancer (NSCLC) w/ no EGFR or ALK genomic tumor aberrations. Locally advanced or metastatic NSCLC after prior chemotherapy. Unresectable locally advanced or metastatic triple-negative breast cancer (TNBC) in combination w/ nab-paclitaxel, for those whose tumors have PD-L1 expression ?1% & who have not received prior chemotherapy for metastatic disease.                              |
| 副作用             | Diarrhea, nausea, vomiting, constipation; fatigue, asthenia, pyrexia, headache; UTI, lung infection; decreased appetite, hypomagnesemia; arthralgia, back pain, musculoskeletal pain; cough, dyspnea; rash, pruritus; anemia, neutropenia, thrombocytopenia; hypothyroidism; dizziness, peripheral neuropathy. Thrombocytopenia, decreased lymphocyte count; hypothyroidism, hyperthyroidism; dysphagia, colitis, abdominal pain, oropharyngeal pain, stomatitis; chills, flu-like illness, infusion-related reaction; increased ALT & AST, hepatitis; hypersensitivity; hypokalemia, hyponatremia, hyperglycemia; hypoxia, nasal congestion, pneumonitis, nasopharyngitis, dysphonia; hypotension; dysgeusia, syncope; proteinuria.                                                                              |
| 禁忌               | Hypersensitivity.                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                 |
| 藥物保存方式       | 避光,2-8℃                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                         |
| 用法用量           | Administer as IV infusion with initial dose over 60 min. If 1st dose is tolerated, all subsequent infusions may be administered over 30 min. Monotherapy 1,200 mg by IV infusion every 3 wk. Combination therapy: Non-squamous NSCLC In combination w/ bevacizumab, paclitaxel, & carboplatin: 1,200 mg by IV infusion, followed by bevacizumab, paclitaxel, & then carboplatin every 3 wk for 4 or 6 cycles during induction phase, then, followed by maintenance phase w/o chemotherapy in which 1,200 mg Tecentriq followed by bevazicumab, is administered by IV infusion every 3 wk. TNBC In combination w/ nab-paclitaxel: 840 mg by IV infusion, followed by 100 mg/m2 nab-paclitaxel. For each 28-day cycle Tecentriq is administered on days 1 & 15, & nab-paclitaxel is administered on days 1, 8 & 15. |
| 肝功能異常         | 無需調整劑量                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                      |
| 腎功能異常         | 無需調整劑量                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                      |
| 懷孕用藥危分級     | 尚未確立                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                          |
| 孕期用藥建議       | N/A                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                               |
| 附帶說明           | [仿單]根據其作用機轉，懷孕女性若接受Tecentriq治療可能導致胎兒傷害。 沒有關於懷孕女性使用Tecentriq的資料。動物試驗已顯示，抑制PD-L1/PD-1途徑會增加發育胎兒的免疫相關排斥風險， 而造成胎兒死亡。使用本藥前，應確認具有生育能力女性的懷孕狀態。應將藥物對胎兒的潛在風險告知具有生育能力的女性病人， 並告知具有生育能力的女性於Tecentriq治療期間以及最後一劑後至少5個月內，應採取有效的避孕措施。                                                                                                                                                                                                                                                                                                                                                                                                                     |
| 哺乳期用藥建議     | N/A                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                               |
| 附帶說明           | [仿單]目前未有atezolizumab進入人體乳汁、對於哺乳嬰兒或乳汁生成影響之資料。 由於人類免疫球蛋白G (IgG)會分泌到人類乳汁中，藥物吸收與對嬰兒可能的傷害不明。 由於Tecentriq可能對哺乳嬰兒造成嚴重不良反應， 應告知女性在治療期間與最後一劑後至少5個月內不得哺乳。                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                      |
| 注射劑給藥建議途徑 | IVD                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                               |
| 乾粉稀釋液         | N/A                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                               |
| 輸注點滴液         | 【N/S】 可選 仿單建議                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                             |
| IVP 用法建議       | N/A                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                               |
| IVD 用法建議       | 給藥：第一次以60分鐘透過裝或不裝有無菌、非致熱原性(non-pyrogenic)、低蛋白結合性的管線內置型過濾器(孔徑尺寸為0.2至0.22微米)靜脈給予。若病人可耐受可以30分鐘進行輸注。請勿經由相同的靜脈管線同時給予其他藥物。不得以靜脈推注(push)或快速灌注(bolus)方式給予                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                         |
| 注意事項           | 1.製備輸注溶液：注入含有0.9%美國藥典規格之氯化鈉注射液的250 mL聚氯乙烯(PVC)、聚乙烯(PE)或聚烯烴(PO)輸注袋中稀釋。僅可使用0.9%氯化鈉注射液稀釋。輕輕反轉以混合稀釋溶液。不可搖晃。 2.儲存溶液：於室溫下，從製備時起算不超過6小時。這包括室溫下輸注液裝於輸注袋 中，以及輸注給藥的時間，或從製備時起算，冷藏於2°C至8°C下不超過24小時。                                                                                                                                                                                                                                                                                                                                                                                                                                                                              |

